Form 4: Alto Neuroscience COO Acquires 131,000 Stock Options

Alto Neuroscience's Chief Operating Officer, Michael Conick Hanley Jr., acquired 131,000 employee stock options with an exercise price of $16.71.

Summary

• Michael Conick Hanley Jr., Chief Operating Officer of Alto Neuroscience, Inc. (ANRO), acquired 131,000 employee stock options.
• The options have an exercise price of $16.71 per share.
• The grant date for these options was February 11, 2026, and they are set to expire on February 10, 2036.
• The vesting schedule dictates that 25% of the shares underlying the option will vest on February 11, 2027, with the remaining shares vesting in monthly installments of 1/48th thereafter, contingent on continuous service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates an insider's increased equity stake and potential confidence in the company's future, though it is a routine compensation event.

Positives

• The acquisition of a significant number of stock options by the Chief Operating Officer indicates management's alignment with shareholder interests and potential confidence in the company's future performance.

Risks

• The vesting of the options is subject to the Reporting Person's continuous service, meaning the options could be forfeited if employment ceases before vesting.
• The ultimate value of the options is dependent on the future stock price of Alto Neuroscience, Inc. exceeding the exercise price of $16.71.

Future Outlook

The filing primarily reports a past insider transaction and does not contain explicit forward-looking statements or guidance beyond the specified vesting schedule of the options.

Industry Context

StockSavvy.ai notes that insider option grants are a common form of executive compensation in the biotechnology and pharmaceutical sectors, aiming to incentivize long-term performance and align management interests with shareholder value creation. This grant to a COO is typical for a company like Alto Neuroscience, which is likely focused on R&D and clinical development.

Comparison to Industry Standards

• The grant of 131,000 options to a Chief Operating Officer is a substantial award, common in growth-oriented biotech companies where executive compensation is often heavily weighted towards equity to align with long-term value creation.
• The 10-year expiration period (until February 10, 2036) is standard for employee stock options, providing a long window for the stock price to appreciate.
• The vesting schedule, with a one-year cliff (25% after one year) followed by monthly vesting, is a widely adopted practice in the tech and biotech industries to encourage executive retention and sustained performance, similar to practices seen at companies like Moderna or BioNTech during their growth phases.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the COO's interests with shareholder value creation.
• Employees: No direct impact on general employees, but reflects executive compensation practices within the company.

Next Steps

• Continued service by the Chief Operating Officer is required to ensure the vesting of the options.
• Future stock price performance of Alto Neuroscience, Inc. will determine the ultimate financial value of these options.

Key Dates

Keywords

Alto Neuroscience, ANRO, Stock Options, Insider Transaction, Form 4, Executive Compensation, Michael Conick Hanley Jr., Chief Operating Officer